[Retracted] Comparison of Efficacy and Safety of TACE Combined with Microwave Ablation and TACE Combined with Cryoablation in the Treatment of Large Hepatocellular Carcinoma
Table 5
Prognostic factors associated with progress free survival.
Factor
Univariate analysis
Multivariate analysis
HR(95% CI)
P-value
HR(95% CI)
P-value
Age (years) (>58 vs. ≤58)
1.448(0.915∼2.293)
0.114
—
—
Gender (male vs. female)
1.681(1.042∼2.713)
0.033
2.165(1.301∼3.566)
<0.001
PS (0 vs. 1–2)
0.937(0.597∼1.470)
0.776
—
—
Etiology (HBV vs. Other)
0.888(0.485∼1.623)
0.698
—
—
Cirrhosis (yes vs. no)
0.732(0.435∼1.231)
0.239
—
—
Tumor number (multiple vs. Single)
2.137(1.321∼3.478)
<0.001
2.225(1.351∼3.664)
0.002
Child-Pugh class (A vs. B)
0.966(0.555∼1.681)
0.902
—
—
AFP level (>400 vs. ≤400)
0.827(0.520∼1.315)
0.422
—
—
PVTT statue (yes vs. no)
2.184(1.344∼3.549)
0.002
1.992(1.196∼3.320)
0.008
Treatment (T-MWA vs. T-CRA)
0.893(0.569∼1.401)
0.621
—
—
Note. T-MWA: TACE combined with microwave ablation; T-CRA: TACE combined with radiofrequency ablation.
